Related Experiment Video
Updated: Aug 19, 2025
Polysome Fractionation and Analysis of Mammalian Translatomes on a Genome-wide Scale
Published on: May 17, 2014
MicroRNA Expression Profile in TSC Cell Lines and the Impact of mTOR Inhibitor
Bartłomiej Pawlik1,2, Szymon Grabia3, Urszula Smyczyńska3
1Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Sporna 36/50, 91-738 Lodz, Poland.
Abstract:
The aim of this study was to assess the potential implication of microRNA on tuberous sclerosis (TSC) pathogenesis by performing microRNA profiling on cell lines silencing TSC1 or TSC2 genes using qPCR panels, before and after incubation with rapamycin. Significant differences in expression were observed between samples before and after rapamycin treatment in nineteen miRNAs in TSC1, five miRNAs in TSC2 and seven miRNAs in controls. Of miRNAs dysregulated before rapamycin treatment, three normalized after treatment in the TSC1 group (miR-21-3p, miR-433-3p, let-7g-3p) and one normalized in the TSC2 group (miR-1224-3p). Of the miRNAs dysregulated before rapamycin treatment in the TSC1 and TSC2 groups, two did not normalize after treatment (miR-33a-3p, miR-29a-3p). The results of the possible targets indicated that there are four common genes with seed regions susceptible to regulation by those miRNAs: ZBTB20, PHACTR2, PLXNC1 and ATP1B4. Our data show no changes in mRNA expression of these targets after rapamycin treatment. In conclusion, results of our study indicate the involvement of miRNA dysregulation in the pathogenesis of TSC. Some of the miRNA might be used as markers of treatment efficacy and autonomic miRNA as a target for future therapy.
Insights
MicroRNA dysregulation is implicated in tuberous sclerosis complex (TSC) pathogenesis. Certain microRNAs may serve as treatment efficacy markers or therapeutic targets for TSC.
Area of Science:
- Genetics
- Molecular Biology
- Biochemistry
Background:
- Tuberous sclerosis complex (TSC) is a genetic disorder.
- The pathogenesis of TSC involves dysregulation of the TSC1/TSC2 complex.
- MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression.
Purpose of the Study:
- To investigate the role of microRNA dysregulation in TSC pathogenesis.
- To assess the impact of rapamycin treatment on miRNA expression in TSC.
- To identify potential miRNA biomarkers and therapeutic targets for TSC.
Main Methods:
- MicroRNA profiling using qPCR panels on TSC1- and TSC2-silenced cell lines.
- Analysis of miRNA expression before and after rapamycin treatment.
- Bioinformatic analysis to predict miRNA targets.
Main Results:
- Significant differences in miRNA expression were observed in TSC1 and TSC2 cells after rapamycin treatment.
- Specific miRNAs (miR-21-3p, miR-433-3p, let-7g-3p, miR-1224-3p) normalized after treatment in respective groups.
- Two miRNAs (miR-33a-3p, miR-29a-3p) remained dysregulated.
- Four common target genes (ZBTB20, PHACTR2, PLXNC1, ATP1B4) were identified, with no change in their mRNA expression post-treatment.
Conclusions:
- MicroRNA dysregulation plays a role in TSC pathogenesis.
- Certain miRNAs show potential as biomarkers for treatment efficacy in TSC.
- Investigating specific miRNAs could lead to novel therapeutic strategies for TSC.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
01:22MicroRNAs